Bevacizumab biosimilar(Hualan Genetic Engineering)

Primary objective: To evaluate the pharmacokinetic (PK) similarity of WBP264 (recombinant anti-human vascular endothelial growth factor monoclonal antibody injection) and Avastin® in healthy male volunteers after a single intravenous administration. Secondary objectives: To evaluate the pharmacokinetic characteristics of WBP264 and Avastin® in healthy male volunteers after a single intravenous administration; To evaluate the safety of WBP264 and Avastin® in healthy male volunteers after a single intravenous administration; To evaluate the immunogenicity of WBP264 and Avastin® in healthy male volunteers after a single intravenous administration.